Kite Pharma, a Gilead company, plans to expand manufacturing capacity with a new biologics facility in Urbana, MD. Kite specializes in cancer treatments and is expanding its ability to provide both clinical and commercial treatments. The facility will focus on chimeric antigen receptor T (CAR-T) therapies, which uses a patient’s white blood cells to destroy cancer cells. Producing these therapies requires complex processes and the new facility will enable the company to better meet these specifi...